普啉索旦
| 中文名称 | 普啉索旦 |
|---|---|
| 中文同义词 | 普啉索旦;化合物 T12720 |
| 英文名称 | Prinoxodan |
| 英文同义词 | Prinoxodan;RGW2938;Prinoxodan (RGW2938);2(1H)-Quinazolinone, 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)- |
| CAS号 | 111786-07-3 |
| 分子式 | C13H14N4O2 |
| 分子量 | 258.28 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 111786-07-3.mol |
| 结构式 |  |
普啉索旦 性质
| 熔点 | >250 °C |
|---|---|
| 密度 | 1.47±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 13.58±0.40(Predicted) |
Phosphodiesterase
Prinoxodan (RG W-2938) is an orally effective positive inotropic/vasodilator agent. Prinoxodan is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vitro in isolated guinea pig hearts; in the latter, Prinoxodan 5 nmol-5 μmol increases contractility in a dose-related fashion.
Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-U00208 | 普啉索旦 Prinoxodan | 111786-07-3 | 1mg | 2500元 |
| 2024/04/30 | HY-U00208 | Prinoxodan | 5 mg | 6200元 |